Aleafia Health Subsidiary Secures Regulatory Approvals for Cannabis Sales in Germany

Published: September 2, 2020

Aleafia Health Subsidiary Secures Regulatory Approvals for Cannabis Sales in Germany

Aleafia Health Inc.’s indirect subsidiary, Aleafia Health Germany GmbH will commence distributing medical cannabis products to German pharmacies following regulatory approvals.

Aleafia Germany has now received a controlled drug licence from the Federal Institute for Drugs and Medical Devices and a European Union Good Distribution Practice certification from the Cologne district government. Together, these approvals authorize Aleafia Germany to purchase and distribute medical cannabis products within Germany from its cannabis distribution centre (DC) in Aachen Brand. Aleafia Germany is expected to begin cannabis sales in September.

Aleafia Health indirectly owns 60 percent of Aleafia Germany, by way of a joint-venture with Acnos Pharma GmbH (Acnos), a German pharmaceutical wholesaler and logistics company, which recently completed its state-of-the-art pharmaceutical production and supply chain facility.

“We are delighted to launch operations in the German market, leveraging the strength of our joint-venture’s existing distribution network,” said Aleafia Health CEO Geoffrey Benic. “This breakthrough allows us to begin capturing market share while working towards the ultimate goal of receiving an EU-GMP Certification for our Paris, Ont. facility.”

“With our state-of-the-art cannabis distribution centre now licensed and operational, Aleafia Germany is well positioned to quickly start selling cannabis products to our wide network of pharmacies across Germany,” said Maximillian Claudel, Acnos Co-Owner and Managing Director of Aleafia Germany.